Forskning ved Københavns Universitet - Københavns Universitet

Forside

Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Andreassen, Mikkel
  • Emma Ilett
  • Dominik Wiese
  • Emily P. Slater
  • Marianne Klose
  • Carsten Palnæs Hansen
  • Norman Gercke
  • Seppo W. Langer
  • Andreas Kjaer
  • Elisabeth Maurer
  • Birgitte Federspiel
  • Peter H. Kann
  • Detlef K. Bartsch
  • Ulrich Knigge

Introduction: Diagnosis and pathological classification of insulinomas are challenging. Aim: To characterize localization of tumors, surgery outcomes, and histopathology in patients with insulinoma. Methods: Patients with surgically resected sporadic insulinoma were included. Results: Eighty patients were included. Seven had a malignant tumor. A total of 312 diagnostic examinations were performed: endoscopic ultrasonography (EUS; n = 59; sensitivity, 70%), MRI (n = 33; sensitivity, 58%), CT (n = 55; sensitivity, 47%), transabdominal ultrasonography (US; n = 45; sensitivity, 40%), somatostatin receptor imaging (n = 17; sensitivity, 29%), 18F-fluorodeoxyglucose positron emission tomography/CT (n = 1; negative), percutaneous transhepatic venous sampling (n = 10; sensitivity, 90%), arterial stimulation venous sampling (n = 20; sensitivity, 65%), and intraoperative US (n = 72; sensitivity, 89%). Fourteen tumors could not be visualized. Invasive methods were used in 7 of these 14 patients and localized the tumor in all cases. Median tumor size was 15 mm (range, 7 to 80 mm). Tumors with malignant vs benign behavior showed less staining for insulin (3 of 7 vs 66 of 73; P = 0.015) and for proinsulin (3 of 6 vs 58 of 59; P < 0.001). Staining for glucagon was seen in 2 of 6 malignant tumors and in no benign tumors (P < 0.001). Forty-three insulinomas stained negative for somatostatin receptor subtype 2a. Conclusion: Localization of insulinomas requires many different diagnostic procedures. Most tumors can be localized by conventional imaging, including EUS. For nonvisible tumors, invasive methods may be a useful diagnostic tool. Malignant tumors showed reduced staining for insulin and proinsulin and increased staining for glucagon.

OriginalsprogEngelsk
TidsskriftJournal of Clinical Endocrinology and Metabolism
Vol/bind104
Udgave nummer12
Sider (fra-til)6129-6138
ISSN0021-972X
DOI
StatusUdgivet - dec. 2019

ID: 241414535